Global Liquid Biopsy Market (2021 to 2026) - by Cancer, Product, Sample, Circulating Biomarkers, Regions and Company Analysis - ResearchAndMarkets.com

The "Liquid Biopsy Market Global Forecast by Cancer, Product, Sample, Circulating Biomarkers, Regions, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

This report provides a detailed analysis of Global Liquid Biopsy Industry. According to the research analysis, Global Liquid Biopsy Market is expected to be US$ 3.1 Billion by 2026.

The 9 Companies Studied in the Report have been Studied from three Points

• Company Overview
• Recent Development
• Financial Insight

By Companies

1. Thermo Fisher Scientific Inc.

2. Roche Diagnostics

3. Bio-Rad Laboratories Inc.

4. Biocept Inc.

5. Biocartis

6. Myriad Genetics, Inc.

7. Genomic Health

8. NeoGenomics Laboratories

9. Qiagen

A liquid biopsy is an emerging tool for the diagnosis of cancer disease nowadays. The liquid biopsy involves collecting samples and analysing tumours in the blood to diagnose cancer disease in the human body. Liquid biopsy assists medical practitioners as a source of genomic and proteomic knowledge in cancer patients by early detection of circulating tumour cells, DNA and extracellular vesicles. Currently, liquid biopsy plays a critical role in accelerating and implementing accurate oncology in clinical settings by leading to an improved understanding of tumour heterogeneity and allowing for dynamic control of reactions to care and variations in genomics.

The major growth drivers of liquid biopsies are that while extracting the tissue sample from the human body is much pain-free, it substitutes the pain associated with the procedure. Besides, liquid biopsy is very accurate in detecting tumour cells in the blood of cancer patients. Due to the low sensitivity of liquid biopsy, it acts as the restraint factor in the market's growth.

The key players play an essential role in the liquid biopsy market's growth by launching innovative products. In June 2020, NeoGenomics Inc. launched three liquid biopsy tests for non-small cell lung cancer, solid tumour types, and specific breast cancer. The COVID-19 effect in the liquid biopsy market has been harsh because all patients are taking therapies to treat cancer; since they have a weak immune system, and they are less prone to fight with coronavirus diseases.

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Market Dynamics

3.1 Growth Drivers

3.2 Challenges

4. Global - Liquid Biopsy Market

5. Market Share - Global Liquid Biopsy

5.1 By Region

5.2 By Cancer

5.3 By Product

5.4 By Circulating Biomarkers

6. Region - Liquid Biopsy Market

6.1 North America

6.2 Europe

6.3 Asia-Pacific

6.4 Latin America

6.5 Middle East & Africa

7. Cancer - Liquid Biopsy Market

7.1 Lung Cancer

7.2 Breast Cancer

7.3 Colorectal Cancer

7.4 Prostate Cancer

7.5 Others

8. By Product - Liquid Biopsy Market

8.1 Kits & Consumables

8.2 Instruments

8.3 Services

9. Circulating Biomarkers - Liquid Biopsy Market

9.1 Circulating Tumor cell (CTCs)

9.2 Circulating Tumor DNA (ctDNA)

9.3 Extracellular Vesicles (EVs)

9.4 Other Biomarkers (cell free DNA,etc)

10. By Clinical Application - Liquid Biopsy Market

10.1 Monitoring

10.2 Prognosis

10.3 Theranostics

10.4 Screening

11. By Sample - Liquid Biopsy Market

11.1 Plasma / Serum

11.2 Urine

11.3 Others

12. Company Analysis

For more information about this report visit https://www.researchandmarkets.com/r/wqh1qh

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005178/en/